-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer (PCa) is one of the most common cancers in men, with more than 1 million men diagnosed with prostate cancer worldwide in 2019. Men with PCa have a higher risk of cardiovascular disease (CVD) than men without PC.
Studies have pointed to an increased risk of cardiovascular disease (CVD) in men with type 2 diabete.
The study was a population-based cohort design and included longitudinal data from 2006 to 2016. Using these data, the researchers established 2 large cohorts consisting of men with and without PCa and men with and without GnRH agonist.
The PCa cohort included 5714 men (median [IQR] age, 70 [10]) and the non-PCa cohort included 28,445 PCa-free men (median [IQR] age, 70 [10].
Cumulative incidence of cardiovascular disease
In conclusion, in this population-based cohort study, men with type 2 diabetes who received GnRH agonists for PCa had an increased risk of CV.
Original source:
E Lin, Hans Garmo, Mieke Van Hemelrijck et a.